<DOC>
	<DOCNO>NCT00679432</DOCNO>
	<brief_summary>The purpose study compare Budesonide MMX™ 6 mg Budesonide MMX™ 9 mg tablet placebo Asacol 6x 400 mg tablet 8-week treatment period determine Budesonide MMX™ effective treatment ulcerative colitis .</brief_summary>
	<brief_title>( CB-01-02/01 ) Randomized Placebo Controlled Trial Budesonide-multi-matrix System ( MMX™ ) 6 mg 9 mg Patients With Ulcerative Colitis</brief_title>
	<detailed_description>Each patient receive one follow regimen morning breakfast : 1. one budesonide-MMX™ 6 mg tablet plus two placebo Asacol® encapsulate tablet , 2. one budesonide-MMX™ 9 mg tablet plus two placebo Asacol® encapsulate tablet , 3. two placebo Asacol® encapsulate tablet plus one placebo budesonide tablet , 4. two Asacol® 400 mg encapsulate tablet plus one placebo budesonide tablet , daily 8 week . Each patient also receive day midday meal even meal either : - two Asacol® 400 mg over-encapsulated tablet ( Group 4 ) , - equivalent placebo Asacol® over-encapsulated tablet , ( Groups 1 , 2 3 ) Hence , patient take seven tablet per day active placebo study medication per randomization schedule . Placebo tablets budesonide-MMX™ placebo over-encapsulated tablet Asacol® use maintain study blind use double-dummy technique . During study , five visit clinical center schedule : one Screening three double-blind treatment period ( Day 1 , Day 14 , Day 28 Day 56 ) . A safety follow visit take place 2 week final study visit . If patient withdrawn study Day 56 , ask attend study center soon possible thereafter Final visit assessment conduct .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients fulfil follow criterion screen visit eligible participation study : Male female patient , 1875 year old , suffer ulcerative colitis least 6 month . Diagnosis ulcerative colitis active phase , mild moderate entity Ulcerative Colitis Disease Activity Index ( UCDAI ) ≥ 4 ≤ 10 accord Sutherland . All female childbearing potential must negative serum pregnancy test immediately prior enrollment . In addition , female childbearing potential must agree completely abstinent use accepted form contraception throughout entire study period . Accepted form contraception define failure rate &lt; 1 % properly apply include : combination oral pill , intrauterine device , sterilise partner stable relationship . Female subject must also actively breastfeed entire study period . Ability comprehend full nature purpose study , include possible risk side effect . Ability cooperate investigator comply requirement entire study . Must able understand voluntarily sign write informed consent prior inclusion study . Patients meet follow criterion screen visit exclude study participation : Patients limited distal proctitis ( anal verge 15 cm pectineal line ) . Patients severe ulcerative colitis ( UCDAI &gt; 10 ) . Patients infectious colitis . Evidence history toxic megacolon . Severe anemia , leucopenia granulocytopenia . Use oral rectal steroid last 4 week . Use immunosuppressive agent last 8 week study . Use anti tumor necrosis factor alpha ( antiTNFα ) agent last 3 month . Concomitant use rectal preparation . Concomitant use antibiotic . Concurrent use cytochrome P450 3A4 ( CYP3A4 ) inducer CYP3A4 inhibitor . Patients intolerance salicylate . Patients verify , presume expected pregnancy ongoing lactation . Patients liver cirrhosis , evident hepatic renal disease insufficiency , and/or severe impairment biohumoral parameter ( i.e . 2 x upper limit normal alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gamma glutamyl transpeptidase [ GGT ] creatinine ) . Patient severe disease organ system . Patients local systemic complication pathological state require therapy corticosteroid and/or immunosuppressive agent . Patients diagnose type 1 diabetes . Patients diagnose , family history , glaucoma . All patient know hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , accord local privacy policy . Participation experimental therapeutic study last 3 month . ( Note : patient participate observational study exclude ) . Any medical condition principal investigator 's opinion would make administration study drug study procedures hazardous subject obscure interpretation adverse event ( AEs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
</DOC>